NYU Data Catalog

Filter by

of 1 Next >
Results Found: 4

  • Myeloma XI Trial: Newly Diagnosed Patients with Multiple Myeloma with Whole Exome Sequencing of Tumour and Peripheral Blood DNA

    Authors
    Graham Jackson
    Description

    Randomised Comparisons, in Myeloma Patients of All Ages, of Thalidomide, Lenalidomide, Carfilzomib and Bortezomib Induction Combinations, and of Lenalidomide and Combination Lenalidomide Vorinostat as Maintenance (Myeloma XI) was a randomized controlled trial which recruited 4420 patients in the United Kingdom who were newly diagnosed with symptomatic or non-secretory multiple myeloma to study the...

    Subject
    Cancer
    Genomics
    Access Rights
    Author Approval Required
    Local Expert
    Gareth J. Morgan

  • Bone marrow microenvironments that contribute to patient outcomes in newly diagnosed multiple myeloma

    Authors
    Samuel A. Danziger
    Mark McConnell
    Jake Gockley
    Mary H. Young
    29 more author(s)...
    Description

    This dataset contains data on the tumor microenvironment from the whole bone marrow of 436 patients who were diagnosed with multiple myeloma and enrolled in the interventional Total Therapy trial series conducted by the University of Arkansas for Medical Sciences. 266 male and 170 female patients were enrolled between February 25, 2004 and January 11, 2014 and completed 25 to 5,241 days of follow-up...

    Subject
    Cancer
    Chronic Disease
    Genomics
    Access Rights
    Free to All
    Local Expert
    Gareth J. Morgan
  • NYU Dataset

    Genome-Wide Screening Identifies Trim33 as an Essential Regulator of Dendritic Cell Differentiation

    Authors
    Ioanna Tiniakou
    Pei-Feng Hsu
    Lorena S. Lopez-Zepeda
    Gorkem Garipler
    16 more author(s)...
    Description

    The development of dendritic cells (DCs) are controlled by the growth factor Flt3 ligand (Flt3L) and its receptor Flt3. This study contained in vitro CRISPR/Cas9-based dropout genetic screening of DC differentiation from HoxB8-FL cells, in vitro validation of the inhibition of mammalian target of rapamycin (mTOR) signaling as a requirement for HoxB8-FL differentiation, and in vivo validation of select...

    Subject
    Genomics
    Access Rights
    Free to All
  • NYU Dataset

    Impaired Proteolysis of Noncanonical RAS Proteins Drives Clonal Hematopoietic Transformation

    Authors
    Sisi Chen
    Rahul S. Vedula
    Antonio Cuevas-Navarro
    Bin Lu
    23 more author(s)...
    Description

    This study demonstrated that loss of LZTR1, or leukemia-associated mutants in the LZTR1 substrate and RAS GTPase RIT1 that escape degradation, drives hematopoietic stem cell expansion and leukemia in vivo. For the study, genome-scale CRISPR/Cas9 screen performed in different variants of the TF-1 cell line genetically-modified to express mutant forms of RIT1 (M90I or F82C) or depleted in LZTR1 by CRISPR/Cas9,...

    Subject
    Cancer
    Genomics
    Access Rights
    Free to All